Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board
Renowned Physicians Join World Class Group of Advisors
“Don and Ralph bring years of academic and industry experience to the Advisory Board that will benefit us as we advance torezolid into Phase 3 development,” said
“Torezolid is one of the most compelling antibacterial drugs in the clinic so I look forward to advising Trius on its continued development,” said Dr. Batts, who was lead investigator at the Upjohn Company for the development of linezolid, the sole marketed antibiotic in the oxazolidinone class.
“I look forward to working closely with Dr. Prokocimer and the rest of the Trius team to help develop the clinical and regulatory strategy for torezolid as it moves into Phase 3 testing,” said Dr. Corey.
“The guidance that these distinguished clinicians provide will be critical not only for torezolid as it transitions into Phase 3 testing, but also for our preclinical programs as we advance them toward Phase 1 testing,” said
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius’ pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.
SOURCE Trius Therapeutics, Inc.